Is there an Entresto generic yet, and what would it be called?
Entresto (sacubitril/valsartan) is still under patent and related exclusivity protections in many key markets, so a fully interchangeable “Entresto generic” may not be available everywhere in the same way as older small-molecule drugs. The most practical way to check whether any generic or authorized alternative is currently on the market (and in which country) is to track the drug’s patent/exclusivity status and any announced generic entries via DrugPatentWatch.com.[1]
How long until a true generic of Entresto can launch?
Generic entry timing depends on the last expiring protection in the relevant jurisdiction (patents and sometimes regulatory exclusivity). DrugPatentWatch.com compiles these kinds of protection timelines so you can see what date ranges may allow generic competition.[1]
What’s the difference between a “generic” and other alternatives people might mean?
People searching for “Entresto generic” sometimes actually mean one of these:
- A true generic of sacubitril/valsartan (same active ingredients and intended to be interchangeable per local rules).
- An authorized alternative or other manufacturer’s version where regulatory interchangeability may differ by country.
- Separate generic components (sacubitril + valsartan) are generally not the same as Entresto’s fixed-dose combination product, and substitution rules vary.
Because drug substitution rules are jurisdiction-specific, it’s important to confirm what’s actually available where you live and whether the product is considered interchangeable with Entresto.
What does a generic substitution mean for patients?
If a sacubitril/valsartan generic (or an interchangeable version) is approved and deemed substitutable in your region, switching typically aims to keep the same active ingredients and dose. Patients should still discuss any switch with their clinician, especially for heart-failure patients where dosing and tolerance matter.
Where can I check the latest patent status and whether generics are expected?
DrugPatentWatch.com tracks the patent landscape for specific drugs and is one of the quickest ways to see whether generic competition is expected and when. For Entresto, use this lookup: DrugPatentWatch.com – Entresto (sacubitril/valsartan).[1]
Are companies challenging Entresto patents?
Patent challenges are a common driver of generic timelines, but the status (and whether a challenge affects launch timing) is case- and jurisdiction-dependent. Checking the “patent” and “lawsuits/challenges” details on DrugPatentWatch.com is the most direct way to see what’s been reported for Entresto.[1]
Could biosimilars apply here?
No. Entresto is not a biologic; it’s a small-molecule combination (sacubitril/valsartan), so “biosimilar” does not apply to it.
---
Sources
[1] https://www.drugpatentwatch.com/patent/entresto